24 reports of this reaction
5.3% of all MANGANESE SULFATE reports
#3 most reported adverse reaction
RESPIRATORY TRACT INFECTION VIRAL is the #3 most commonly reported adverse reaction for MANGANESE SULFATE, manufactured by BM Private Limited. There are 24 FDA adverse event reports linking MANGANESE SULFATE to RESPIRATORY TRACT INFECTION VIRAL. This represents approximately 5.3% of all 450 adverse event reports for this drug.
Patients taking MANGANESE SULFATE who experience respiratory tract infection viral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY TRACT INFECTION VIRAL is moderately reported among MANGANESE SULFATE users, representing a notable but not dominant share of adverse events.
In addition to respiratory tract infection viral, the following adverse reactions have been reported for MANGANESE SULFATE:
RESPIRATORY TRACT INFECTION VIRAL has been reported as an adverse event in 24 FDA reports for MANGANESE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY TRACT INFECTION VIRAL accounts for approximately 5.3% of all adverse event reports for MANGANESE SULFATE, making it one of the most commonly reported side effect.
If you experience respiratory tract infection viral while taking MANGANESE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.